Monitoring hub

Compounded Prescription Monitoring Center

Current verified alerts; facility changes; recalls; inspections; states; medications; status methodology.

What is established about current verified alerts?

For compounded prescription monitor, current verified alerts is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where current verified alerts has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about facility changes?

For compounded prescription monitor, facility changes is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where facility changes has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about recalls?

For compounded prescription monitor, recalls is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where recalls has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about inspections?

For compounded prescription monitor, inspections is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where inspections has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about states?

For compounded prescription monitor, states is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where states has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What does this page establish?

It establishes the framework and the source map for compounded prescription monitor, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.

What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.

Status terms on this page follow the platform's published status vocabulary.

Why compounded prescription monitor is hard to verify

Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.

First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.

That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.

What can actually be monitored, and what cannot?

Monitoring implies continuous observation, and it is worth being precise about what that means here. Federal registration status is genuinely monitorable: FDA publishes the outsourcing facility register weekly, so a change is detectable within days.

State licensure is monitorable in principle and hard in practice. There are 51 separate registers with different interfaces, different update frequencies and different retention policies. There is no national feed, and building one means 51 separate captures.

Enforcement records — Form 483s, warning letters, recalls — are published but not on a predictable schedule, and the closeout status that determines whether an action is current frequently lags the action itself. Monitoring these means watching for changes rather than reading a current-state feed.

Why does this platform publish gaps rather than estimates?

Because an estimate about a named business is a claim about that business, and the cost of being wrong falls on the entity rather than on the publisher. A pharmacy wrongly shown as unlicensed loses customers; the site that showed it loses nothing.

The alternative most comparison sites choose is to fill gaps with inference and label the result a score. That produces a complete-looking page from incomplete data, and the incompleteness becomes invisible precisely where it matters most.

The trade is that pages here look unfinished. That is the intended appearance: a visible gap tells a reader exactly what to go and check, which is more useful than a confident number they cannot verify.

What this currently costs

Price is one of the few variables a reader can act on directly, so it is reported here rather than left to a separate page. Among the programmes this platform has verified by recomputation, the lowest regular injection rate is $145 per month on the longest commitment tier (NexLife), against higher rates on shorter terms.

Every tier behind that figure was recomputed from the published total rather than taken from the advertised per-month rate — 16 of 18 reconcile exactly, and the two that do not are published with the corrected figure on the regular injection affordability page.

The timeline that closed the compounded GLP-1 market

The compounded GLP-1 market rested on one legal fact: while a drug sits on the FDA shortage list, the bar against compounding an essentially-a-copy product lifts. Both shortages are over, and the exception closed with them. This is the exact sequence, each step traceable to an FDA order or a court decision.

Two consequences follow that are easy to miss. First, the 503A and 503B deadlines were different — 18 February and 19 March 2025 — so a pharmacy and an outsourcing facility were operating under different rules for a month. Second, the April 2026 bulks-list proposal would close the route permanently rather than temporarily: even a future shortage would not reopen it if the substances are formally excluded.

All 17 records in this section

Sources

• FDA — Information for Outsourcing Facilities
• FDA — Q&A: Outsourcing Facility Registration
• FDA — Registered Outsourcing Facilities
• FDA — Aligning Federal and State Regulation of Compounders
• FDA — Outsourcing Facility Fees
• FDA — Compounded Drug Products That Are Essentially Copies
• FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
• FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
• Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
• FDA — Outsourcing Facility Fees guidance

Update history

Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.